Celon Pharma has registered a phase 2 clinical trial to examine the efficacy of a PDE10A inhibitor in reducing L-dopa-induced dyskinesia, which is estimated to completein October 2024 (NCT05297201). This evidence concerns the gene PDE10A and drug-induced dyskinesia.